Key Developments For RTI Biologics, Inc.
RTI Biologics, Inc. (RTIX.O) (Consolidated Issue listed on NASDAQ Global Market)
RTI Biologics Inc. Reaffirms FY 2009 Guidance
RTI Biologics Inc. reiterated that for fiscal 2009, revenues is expected to be in the range of $166-$168 million with earnings per share (EPS) expected to be in the range of $0.11-$0.13. According to Reuters Estimates, analysts are expecting the Company to report EPS of $0.11 for the same period.
RTI Biologics Inc. Reaffirms FY 2009 Guidance
RTI Biologics Inc. reiterated that for fiscal 2009, revenues is expected to be in the range of $166-$168 million with earnings per share (EPS) expected to be in the range of $0.11-$0.13. According to Reuters Estimates, analysts are expecting the Company to report EPS of $0.11 for the same period.
RTI Biologics Inc. Expands Distribution and Supply Agreement with Davol for Tutoplast Sterilized Dermal Allografts
RTI Biologics Inc. announced that it has signed an expanded agreement with Davol Inc., a subsidiary of C.R. Bard Inc. Under the agreement, which is effective immediately, RTI will supply Tutoplast sterilized dermal allografts for exclusive worldwide distribution by Davol for breast reconstruction applications. The agreement also extends Davol`s exclusive worldwide distribution rights for dermal allografts for use in hernia repair for ten years. The new agreement includes a payment for exclusive distribution rights in the breast reconstruction market and potentially two additional payments based on growth milestones in the hernia and breast reconstruction markets.
RTI Biologics Inc. Reiterates FY 2009 Outlook
RTI Biologics Inc. reiterated its fiscal 2009 outlook and expects revenues to be $166-$168 million with fully diluted earnings per share (EPS) of $0.11-$0.13.
RTI Biologics Inc. Announces Distribution and Supply Agreement with Aesculap for Biocleanse-Sterilized Spinal Allografts
RTI Biologics Inc. announced that it has signed an agreement to provide spinal allograft implants to Aesculap Implant Systems, Inc. Under the agreement, which is effective immediately, RTI will process cervical and lumbar spinal grafts from designs developed by Aesculap Implant Systems.
